Predictive Oncology Inc.
POAI
$5.89
$0.346.13%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 84.03% | -31.81% | -46.81% | -60.16% | -77.65% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 84.03% | -31.81% | -46.81% | -60.16% | -77.65% |
| Cost of Revenue | 25.23% | -2.90% | -30.87% | -45.43% | -45.54% |
| Gross Profit | 244.31% | -47.52% | -55.40% | -68.42% | -91.42% |
| SG&A Expenses | -5.47% | -23.25% | -32.90% | -24.41% | -27.65% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -4.70% | -22.65% | -32.82% | -25.29% | -28.23% |
| Operating Income | 7.83% | 21.83% | 31.24% | 20.67% | 22.17% |
| Income Before Tax | -653.95% | 27.77% | 32.17% | 21.66% | 38.13% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -653.95% | 27.77% | 32.17% | 21.66% | 38.13% |
| Earnings from Discontinued Operations | 88.58% | 43.69% | -23.35% | -168.60% | -581.11% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -503.68% | 30.35% | 26.33% | 9.44% | 24.18% |
| EBIT | 7.83% | 21.83% | 31.24% | 20.67% | 22.17% |
| EBITDA | 7.93% | 21.20% | 30.08% | 17.84% | 17.93% |
| EPS Basic | -162.91% | 59.00% | 49.94% | 27.41% | 34.06% |
| Normalized Basic EPS | -221.58% | 58.03% | 53.84% | 36.31% | 30.49% |
| EPS Diluted | -162.49% | 58.98% | 49.87% | 27.23% | 33.93% |
| Normalized Diluted EPS | -221.58% | 58.03% | 53.84% | 36.31% | 30.49% |
| Average Basic Shares Outstanding | 76.16% | 74.37% | 54.08% | 35.77% | 20.43% |
| Average Diluted Shares Outstanding | 76.16% | 74.37% | 54.08% | 35.77% | 20.43% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |